Alunbrig (brigatinib) vs Augtyro (repotrectinib)

Alunbrig (brigatinib) and Augtyro (repotrectinib) are both targeted therapies used to treat certain types of non-small cell lung cancer (NSCLC) that have specific genetic mutations. Alunbrig is specifically designed to inhibit anaplastic lymphoma kinase (ALK) and is approved for patients with ALK-positive metastatic NSCLC. In contrast, Augtyro (repotrectinib) targets not only ALK but also ROS1 and NTRK, and is used for the treatment of solid tumors with these specific gene rearrangements, although as of the last update, it may still be under clinical investigation and not yet approved for use. Patients should consult with their oncologist to determine which medication is most appropriate for their specific genetic mutation and disease profile.

Difference between Alunbrig and Augtyro

Metric	Alunbrig (brigatinib)	Augtyro (repotrectinib)
Generic name	Brigatinib	Repotrectinib
Indications	Non-small cell lung cancer (NSCLC) with ALK mutations	Advanced solid tumors with NTRK or ROS1 gene fusions
Mechanism of action	ALK and EGFR inhibitor	TRK, ROS1, and ALK inhibitor
Brand names	Alunbrig	Augtyro
Administrative route	Oral	Oral
Side effects	Nausea, diarrhea, fatigue, cough, headache	Fatigue, constipation, dizziness, edema, anemia
Contraindications	Hypersensitivity to brigatinib, severe hepatic impairment	Hypersensitivity to repotrectinib, severe hepatic impairment
Drug class	Tyrosine kinase inhibitor	Tyrosine kinase inhibitor
Manufacturer	Takeda Oncology	Turning Point Therapeutics, Inc.

Efficacy

Alunbrig (brigatinib) Efficacy in Lung Cancer

Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of patients with non-small cell lung cancer (NSCLC) that is ALK-positive. Clinical trials have demonstrated that brigatinib is effective in treating NSCLC that has spread to other parts of the body. In a pivotal trial, patients treated with brigatinib had a median progression-free survival (PFS) that was significantly longer compared to those who received crizotinib, another ALK inhibitor. Additionally, brigatinib has shown activity against central nervous system (CNS) metastases, which is a common complication in advanced NSCLC.

The efficacy of Alunbrig has been evaluated in several clinical settings, including as a first-line treatment and in patients who have progressed on crizotinib. The response rates in patients receiving Alunbrig as a first-line treatment are particularly encouraging, with a significant proportion of patients achieving a partial or complete response. This highlights the potential of brigatinib to improve outcomes for patients with ALK-positive NSCLC.

Augtyro (repotrectinib) Efficacy in Lung Cancer

Augtyro (repotrectinib) is an investigational new drug that targets tropomyosin receptor kinases (TRK), ROS1, and ALK. It is currently being studied for its efficacy in treating lung cancer, including NSCLC with ROS1 or NTRK fusions and ALK-positive NSCLC. While repotrectinib has not yet received FDA approval, early clinical trials have shown promising results in patients with these specific genetic alterations.

In early-phase clinical trials, repotrectinib has demonstrated a high level of activity in patients with ROS1-positive NSCLC, including those who have previously been treated with other ROS1 inhibitors. The drug has been designed to overcome resistance to prior therapies, and the initial data suggests that it may be effective in this regard. Moreover, repotrectinib has shown a manageable safety profile, which is important for patient quality of life during treatment. Ongoing trials continue to evaluate the efficacy and safety of repotrectinib in a larger cohort of patients with lung cancer.

Regulatory Agency Approvals

Alunbrig

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Augtyro

Food and Drug Administration (FDA), USA

Access Alunbrig or Augtyro today

If Alunbrig or Augtyro are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Alunbrig

Buy Augtyro

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: